The clinical trial enrolled patients at different sites around the world who were receiving opioid substitution therapy. A majority of participants continued to use drugs illicitly during the study period. Participants adhered to their HCV treatments at a rate of 95 percent, which is comparable to adherence rates in clinical trials that do not enroll individuals exhibiting continual drug use. Of the 301 participants enrolled, six probable reinfections were detected during 24-week follow ups.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Lead investigator, Gregory Dore, PhD, of the Kirby Institute at the University of New South Wales in Australia, said, “I am optimistic that the results from this study will help to reduce stigma associated with drug use and hepatitis C infection and really open up access to hepatitis C treatment globally.”
More articles on infection control:
Arizona measles outbreak comes to official end
New drug targeting three deadly parasitic infections shows promise in mouse study
Maryland hospital shuts down NICU after deadly bacteria discovered
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
